Given that combination therapy with a PD1 inhibitor and chemotherapy has shown benefits in ESCC clinical trials, we further analyzed treatment-related checkpoint molecule expression in T cells. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.